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Background: In cancer cells, apoptosis is an important mechanism that influences the outcome of chemotherapy
and the development of chemoresistance. To find the genes involved in chemoresistance and the development of
gastric cancer, we used the suppression subtractive hybridization method to identify the genes that are
overexpressed in gastric cancer tissues compared to normal gastric tissues.
Results: In the suppression subtractive hybridization library we constructed, the most highly overexpressed genes
were humanin isoforms. Humanin is a recently identified endogenous peptide that has anti-apoptotic activity and
has been selected for further study due to its potential role in the chemoresistance of gastric cancer. Upregulation
of humanin isoforms was also observed in clinical samples by using quantitative real-time PCR. Among the studied
isoforms, humanin isoform 3, with an expression level of 4.166 ± 1.44 fold, was the most overexpressed isoform in GC.
Conclusions: The overexpression of humanin in gastric cancer suggests a role for chemoresistance and provides new
insight into the biology of gastric cancer. We propose that humanin isoforms are novel targets for combating
chemoresistance in gastric cancer.
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Gastric cancer (GC) is the fourth most common type of
malignancy and the second leading cause of cancer mor-
tality, which has increased in developing countries [1,2].
Different genetic and epigenetic alterations are involved in
the development of GC which include alterations in onco-
genes (c-erbB2), tumor suppressor genes (p53), DNA re-
pair genes (hMLH1), cell cycle regulators (cyclin E), and
signaling molecules (TGFB1/2) [3,4]. Identification of the
molecular mechanisms that contribute to the pathogenesis
of GC could help us find targets for early diagnosis, classi-
fication, and treatment of it [2]. Although some gene al-
terations have been identified in GC, the fundamental* Correspondence: nsetayesh@tums.ac.ir
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article, unless otherwise stated.molecular mechanisms leading to it need to be elucidated
[5-7]. Finding the genes that are differentially expressed in
GC is one of the best approaches in establishing new bio-
markers and therapeutic targets. In addition, these studies
could improve our knowledge about molecular biology
and carcinogenesis of GC.
Chemotherapy has been an important treatment for
gastrointestinal cancers [2], although its success rate is
limited due to chemoresistance (e.g. resistance to cis-
platin, 5-fluorouracil, mitomycin C or doxorubicin). It is
widely accepted that the apoptotic capacity of cancer
cells is critical in determining its response to chemother-
apeutic agents. The anti-apoptotic nature of cancer cells
becomes a mechanism in its chemoresistance, and al-
lows the tumor to survive [8,9]. In addition cell survival
processes have an important role in chemoresistance;
autophagy has been identified in chemoresistance and ised Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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stages of carcinogenesis. Autophagy is increased by the
level of stress but the resulting event varies which could
either lead to survival by inhibition of autophagy or to an
apoptotic cell death [10]. Many high throughput studies
have documented the genes alterations in GC [3,4], al-
though they failed to encompass a complete view of their
molecular pathogenesis and chemoresistance. Along with
these studies, towards establishing more data about the
genes alterations in GC, our research used suppression
subtractive hybridization (SSH), a high throughput gene
expression analysis method: this requires no prior know-
ledge about gene selection. The SSH is a method of select-
ive amplification of differentially expressed sequences,
which overcomes the technical drawbacks of traditional
subtraction methods. Some of the advantages of the
SSH method include minute amounts of required initial
mRNA, elimination of the need for physical separation of
single- and double-stranded molecules, equalization of the
abundance of mRNA sequences within the target popula-
tion and suitable for detection of rare transcripts [11].
In our study, among the identified genes from the con-
structed SSH library, we found four isoforms of Huma-
nin (HN, HN1 [EMBL: CR612552, GenBank: AC131055,
Swiss-Prot: P0CJ68], HN3 [EMBL: AL109955, GenBank:
AL135939, Swiss-Prot: P0CJ70], HN6 [EMBL: AC231380,
GenBank: AC231380, Swiss-Prot: P0CJ73], and HN10
[EMBL: AL158819, GenBank: AL158819, Swiss-Prot:
P0CJ77]) as the overexpressed genes in GC. While it has
been demonstrated that Humanin (HN) bears an endo-
genous synthesis source [12], the precise origin of its gene
(or genes) is not specified [13]. HN is a recently identified
endogenous peptide that protects cells against cytotoxicity
and suppresses apoptosis caused by various stimuli, e.g.,
serum deprivation, UV irradiation, or staurosporine [13].
The cytoprotective effects of HN seems to be through
various mechanisms including its antiapoptotic, metabolic
(improvement of the mitochondrial bioactivity) and anti-
inflammatory effects [14]. Furthermore, considering the
antiapoptotic effects of HN through its binding to Bax, a
Bcl-2 family pro-apoptotic protein [15], HN could mask
pro-apoptotic effects of chemotherapy agents.
We provide new information about genes associated
with the development of GC, particularly those involved
in the chemoresistance of cancer cells: this can have a
significant influence on treatment for this type of cancer
that could be considered as a target in drug discovery in
combating chemoresistance in gastric cancer, which typ-
ically has a poor prognosis.
Methods
Tissue sample preparation
In establishing the main SSH library, both normal and
tumor gastric tissues were collected from a 64-year-oldmale patient during surgery. A pathologist dissected the
target tissues under the microscope with special care
for minimal contamination of nonepithelial cells, and
RNAlater® (Ambion, Austin, TX, USA) was used to
stabilize the RNA during storage. Hematoxylin–eosin
(H&E) staining was done on the tissue to determine the
tumor type and its degree of invasion.
In order to check the expression of the differentially
expressed genes by quantitative real-time PCR (qRT-PCR),
ten clinical tissue samples (five tumor and five normal
samples) were collected from patients with endoscopy: all
samples were obtained prior to chemotherapy. The con-
sent form of The Biologic Sampling Ethics Committee,
Tehran University of Medical Sciences (TUMS) was re-
ceived from each patient before surgery or endoscopy.
Total RNA extraction
Total RNA was extracted from tissues with the TriPure
Isolation Reagent (Roche Applied Science, Indianapolis,
IN, USA). Its concentration and purity were analyzed
using the Biophotometer (Eppendorf, Hamburg, GY),
and its integrity was visually checked with 1% denatured
agarose gel.
mRNA isolation
Isolation of mRNA was done with the DynaBead® mRNA
Isolation Kit (Dynal, Lake Success, NY, USA). Briefly,
the appropriate amount of DynaBeads oligo (dT)25 was
equilibrated with 100 μl of binding buffer (100 mM
Tris–HCl, 500 mM LiCl, 10 mM EDTA, 1% LiDS, and
5 mM DTT). Diluted total RNA and equilibrated Dyna-
Beads were then mixed and incubated for 5 min at 37°C in
a shaking incubator. The beads were washed twice using
200 μl of washing buffer (10 mM Tris–HCl, 0.15 M LiCl,
and 1 mM of EDTA). 10 μl of elution buffer was added to
the DynaBeads and incubated for 2 min at 67°C. The
DynaBeads were placed on the magnet, and the eluted
mRNA in supernatant was then isolated. The purified
mRNA was checked with 1% denatured agarose gel.
Suppression subtractive hybridization (SSH)
Using the SSH method, the subtracted library can be
created from one sample pair (including cancerous and
normal tissues) in both forward and reverse directions,
while the expression of the achieved genes are checked
in clinical tissue samples with analysis methods that in-
cluded qRT-PCR [16]. In this study, SSH was carried out
with the PCR-Select™ cDNA Subtraction Kit (Clontech,
Palo Alto, CA, USA) according to the manufacturer’s
protocol. In summary, first- and second-strand cDNA
were synthesized using 2 μg mRNA from the gastric
cancerous (tester) and normal (driver) tissues, and
digested with Rsa I. For the reverse subtraction, the
tester was used as driver, and the driver was used as
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and special adaptors were added to each. After two hy-
bridizations between the tester and driver (towards elim-
inating non-altered genes in the two samples), the
remaining differentially expressed sequences were ampli-
fied with two PCR rounds using Pwo enzyme to reduce
any background products and to enrich the differentially
expressed sequences. For identification of the differen-
tially overexpressed genes, the constructed library (prod-
ucts of the secondary PCR step of SSH) was then cloned
and sequenced as the following steps.
Cloning and confirmation of the positive clones
The secondary PCR product of the SSH method was puri-
fied with the PCR Product Purification Kit (Roche Applied
Sciences, Indianapolis, IN, USA), cloned into pUC19
plasmid vectors and transformed into Escherichia coli
NovaBlue competent cells (Novagen, Madison, WI, USA).
Randomly selected positive colonies were first confirmed
with a colony PCR, using N1 and N2R primers (Table 1).
Plasmids from the confirmed positive clones were isolated
by the High Pure Plasmid Isolation Kit (Roche Applied
Sciences, Indianapolis, IN, USA) and used in single direc-
tion DNA sequencing with the BigDye Terminator Version
3.1 Sequencing Kit and a 3730xl Automated Sequencer
(Applied Biosystems, Foster City, CA, USA). To identify
these sequences, similarity searches were carried out with
BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
Analysis of the subtraction efficiency
Real-time PCR was used to estimate the efficiency of sub-
traction by comparing the abundance of a non-differentially
expressed gene (a housekeeping gene: beta actin) before
and after subtraction. Reactions were prepared by adding
10 μl of SYBR Premix Ex Taq (Takara, Kusatsu, Japan), 1 μl
of the sample, 0.8 μl of the primers (10 μM), 0.4 μl of ROX
dye and DEPC-treated water to a final volume of 20 μl. TheTable 1 Designed primers sequences used to quantify gene e
Primer name Accession number Length Sequence (5′ to
HN1-F NM_001190452.1 20 CGCAGGCCCTAA
HN1-R NM_001190452.1 20 TGCTACTGTCGA
HN3-F NM_001190472.1 20 GGTGATAGCTGG
HN3-R NM_001190472.1 20 ATTAGTGGCTGC
HN6-F NM_001190487.1 20 TTTACCCAGGCG
HN6-R NM_001190487.1 22 GGCTCAGTAGGC
HN10-F NM_001190708.1 23 CGAGAAGACCC
HN10-R NM_001190708.1 20 AGGTTGCTCGGA
N1 Based Ligated Adaptor 22 TCGAGCGGCCGC
N2-R Based Ligated Adaptor 20 AGCGTGGTCGCG
ACTB-F NM_001101.3 21 ATGGCCACGGCT
ACTB-R NM_001101.3 21 CAGGAGGAGCAthermal program for the reaction cycles was 10 min at
95°C, followed by 40 cycles of 30 sec at 95°C, and 1 min at
60°C. Melting curve analysis was done by increasing the
temperature from 65°C to 95°C in 0.1°C/sec increments for
each fluorescence acquisition, using the Step-One-Plus
Apparatus (Applied Biosystems, Foster City, CA, USA).
Relative expression of the beta actin gene in the subtracted
and non-subtracted samples was used in the calculation of
subtraction efficiency.
Quantitative real-time PCR (qRT-PCR)
Quantitative expression analysis was performed with real-
time PCR (Applied Biosystems, Foster City, CA, USA)
for the SSH-identified HN isoforms. Primer design was
done with PrimerSelect, Version 7.1.0 (DNAstar, Madison,
WI, USA) and synthesized by the TAG Company (TAG
Copenhagen, Copenhagen, Denmark) (Table 1). The qRT-
PCR was run with SYBR Premix Ex Taq (Takara, Kusatsu,
Japan) in a final volume of 20 μl, containing 2X master
mix 10 μl, each with forward and reverse primers (10 μM)
1 μl, ROX dye II 0.4 μl, and cDNA 2 μl.
The PCR thermocycle program was set at 95°C for
10 min followed by 40 cycles of 95°C for 30 sec, 62°C for
30 sec. Melt curve analysis followed the PCR step and in-
creased the temperature from 65°C to 95°C, with 0.1°C/sec
increments in each fluorescence reading.
Statistical analysis
The relative gene expression of HN isoforms in tumor
and normal tissues was analyzed using the Livak method
[17]. The statistical significance was set at P < 0.05.
Results
Histological examination
Histological results indicated that the tumor was a mod-
erately differentiated, mucin-producing type of gastric
adenocarcinoma, located in the prepyloric area. Localxpression by real-time PCR
3′) Annealing temp Location Product size
ACTACCAG 61°C 1091-1110
206 bp
TGTGGACC 1277-1296
CTGGCTTA 59°C 180-199
164 bp
TTTTGGGC 324-343
CAGTGGAC 62°C 60-79 247 bp
TTATCACCAC 285-306
TATGTATGGAGC 61°C 603-625
137 bp
GGTTGAAT 720-739
CCGGGCAGGT
68°C
GCCGAGGT
GCTTCCAGC 60°C 763-783
322 bp
ATGATCTTGA 1064-1084
Figure 2 Constructed suppression subtractive hybridization
library. (A) Forward library reveals differentially expressed genes.
Lane 1: Primary PCR enrichment, Lane 2: Secondary PCR enrichment,
Lane 3: Ladder. (B) Analysis of the subtraction efficiency. The relative
expression levels of the beta actin gene in the non-subtracted and
subtracted samples indicate that there is an 8.9-fold decrease in beta
actin expression in the subtracted cDNAs.
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six pre-gastric lymph nodes (Figure 1).
Suppression subtractive hybridization (SSH)
Cloning of the two subtracted libraries (forward and re-
verse), ranged from 100–800 base pairs in size (Figure 2A),
resulted in 120 clones. Among the overexpressed genes
from the forward library, three clones had sequences, which
were identical to four isoforms of HN; HN1, HN3, HN6,
and HN10. They were selected for qRT-PCR analysis due
to their probable role in the chemoresistance of GC cells.
Subtraction efficiency
Real-time PCR analysis demonstrated that beta actin has
an 8.9-fold reduction in the subtracted library, compared
with the non-subtracted library (Figure 2B). This resulting
reduction verified the accuracy of the applied method in
finding differentially expressed genes in GC.
Quantitative real-time PCR (qRT-PCR)
To confirm the results obtained from the constructed SSH
library, relative gene expression of HN isoforms was
checked in some endoscopic tissue samples. The results
showed overexpression of HN isoforms in clinical tissue
samples (Figure 3). These results confirmed the efficiency
of the SSH library, which also indicated that these isoforms
were significantly overexpressed in GC. Between the stud-
ied isoforms, HN3 with an expression level of 4.166 ± 1.44
fold was the most overexpressed isoform in GC.
Discussion
This study focused on the overexpressed genes associ-
ated with gastric adenocarcinoma as the most prevalent
and life-threatening type of cancer in Iran [18]. Che-
moresistance of tumor cells is a therapeutic defeat that
affects treatment outcomes with cancer [19]. Develop-
ment of resistance is a common occurrence in GC, with
apoptosis considered to be one of the major mechanisms
in tumorigenesis and chemoresistance of cells [9,19].Figure 1 Histological features of the resected gastric cancerous tissue
(A) Tubular structure formation, which characterizes these cancerous cells as a
be determined by the white matrix surrounded the cancerous cells. (C) Cross
the gastric adenocarcinoma cells and lymph node follicles could be observedTwo important mechanisms involved in this resistance
are the loss of pro-apoptotic signals and the gain of anti-
apoptotic mechanisms [20].
Using SSH in this study, HN isoforms, the anti-apoptotic
endogenous peptides with a potential role in the chemo-
resistance of GC cells were identified. Furthermore,
upregulation of identified HN isoforms were confirmed
using qRT-PCR. The importance of this study is the spe-
cific isoforms of HN identified as the overexpressed genes
in GC (HN isoforms 1, 3, 6 and 10). Due to the high simi-
larities between HN isoforms and lack of isoform-specific
antibodies, detection of HN isoforms at the protein level
by western blotting or IHC was not provided in this study.
Our study identified the HN gene as an overexpressed
gene in GC. It is a newly discovered 24-amino acid pep-
tide; with 75 bases in an open reading frame and 950
bases downstream of the 5′ end of the HN cDNA (HN
cDNA is 99% similar to mitochondrial DNA) [21,22].stained by H&E to determine the cancer type and metastasis.
n adenocarcinoma tumor type. (B) Mucin producing type of GC could
-sectional analysis of a pre-gastric lymph node. The tubular formation of
.
Figure 3 Relative gene expression analysis of HN isoforms in normal and tumor tissue samples, using qRT-PCR. (A) HN1 isoform. (B)
HN3 isoform. (C) HN6 isoform. (D) HN10 isoform. N-GT: normal gastric tissue, T-GT: tumor gastric tissue. Whiskers represent the STDEV of expression in
samples (n = 10). *P < 0.05, **P < 0.01.
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to BAX, tBID, and BimEL and executes its anti-apoptotic
activity through selective attachment to BAX and trans-
location inhibition of BAX to the mitochondria [15,23,24].
There have been many in vitro studies demonstrating the
protective characteristic of HN in different cell types
[25-29]. The results suggest that HN could increase the
energy produced by mitochondria [30]. Furthermore, HN
could similarly increase the ATP- vs. pyrovate-biogenesis,
which leads to the assumption that HN may have an im-
portant role in mitochondrial dysfunction-related diseases,
including cancer [23,30,31]. HN overexpression in GCcould be related to stress in a microenvironment of cancer
cells (e.g., nutrient deprivation) that triggers apoptosis
[24]. Cancer cells, along with the upregulation of the HN
gene as an anti-apoptotic factor, combated apoptosis in
them. In addition, nutrient deprivation and continuous
cell division demanded additional energy resources. In this
way, HN as a function of ATP production in cancer cells
could diminish metabolic stresses.
Our results showed that HN3, with a 4.166 ± 1.44 -fold
increase in GC tissues, is the dominant isoform. HN iso-
forms have a unique coding sequence for the HN peptide.
Various isoforms in the HN gene with different 5′-UTR
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of its peptide. Peptides with the highest stability, with
increased residence time in cancer cells, could also
have more influence in tumorigenesis and chemore-
sistance [32].
Our results suggest that upregulation of HN in GC
could be an important molecular event in its tumorigen-
esis. Given its anti-apoptotic activity in cancer cells, it
could be one of the fundamental mechanisms in che-
moresistance of GC cells: upregulation of HN alleviates
metabolic stresses by ATP production which could have
an important role in the early stages of tumorigenesis.
HN can potentially serve as a new biomarker in the
diagnosis of GC since it is present in blood circulation.
To date, HN was not considered a key gene in the che-
moresistance of tumor cells; future studies that target
HN in gastric chemoresistance cells may have a valu-
able impact on the therapeutic modality used for this
cancer.Conclusions
In conclusion, using the SSH method, the overexpres-
sion of HN 1, 3, 6, and 10 isoforms were identified for
the first time in gastric cancer cells. Considering the fun-
damental role of anti-apoptosis in the chemoresistance
of cancer cells and the high expression level of HN in
GC, further studies are needed to evaluate the role of
HN isoforms and chemoresistance. In addition, since
overexpression of HN isoforms could lead to chemore-
sistance in GC this gene could be a candidate in drug
discovery investigations for targeting chemoresistance in
this cancer.
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